These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1505072)

  • 1. Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects.
    Bhuyan BK; Smith KS; Adams EG; Wallace TL; Von Hoff DD; Li LH
    Cancer Chemother Pharmacol; 1992; 30(5):348-54. PubMed ID: 1505072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells.
    Bhuyan BK; Smith KS; Adams EG; Petzold GL; McGovren JP
    Cancer Res; 1992 Oct; 52(20):5687-92. PubMed ID: 1394193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance is a component of V79 cell resistance to the alkylating agent adozelesin.
    Bhuyan BK; Smith KS; Kelly RC; Adams EG; Abraham I; Sampson KE
    Cancer Res; 1993 Mar; 53(6):1354-9. PubMed ID: 8443816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.
    Smith KS; Folz BA; Adams EG; Bhuyan BK
    Cancer Chemother Pharmacol; 1995; 35(6):471-82. PubMed ID: 7533669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.
    Nguyen HN; Sevin BU; Averette H; Perras J; Hightower R; Ramos R; Donato D; Penalver M
    Cancer Chemother Pharmacol; 1992; 30(1):37-42. PubMed ID: 1586978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The DNA minor groove-alkylating cyclopropylpyrroloindole drugs adozelesin and bizelesin induce different DNA damage response pathways in human colon carcinoma HCT116 cells.
    Cao PR; McHugh MM; Melendy T; Beerman T
    Mol Cancer Ther; 2003 Jul; 2(7):651-9. PubMed ID: 12883038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The A/T-specific DNA alkylating agent adozelesin inhibits Plasmodium falciparum growth in vitro and protects mice against Plasmodium chabaudi adami infection.
    Yanow SK; Purcell LA; Spithill TW
    Mol Biochem Parasitol; 2006 Jul; 148(1):52-9. PubMed ID: 16597469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor drug adozelesin differentially affects active and silent origins of DNA replication in yeast checkpoint kinase mutants.
    Wang Y; Beerman TA; Kowalski D
    Cancer Res; 2001 May; 61(9):3787-94. PubMed ID: 11325853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adozelesin triggers DNA damage response pathways and arrests SV40 DNA replication through replication protein A inactivation.
    Liu JS; Kuo SR; McHugh MM; Beerman TA; Melendy T
    J Biol Chem; 2000 Jan; 275(2):1391-7. PubMed ID: 10625690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of U-71,184 and several other CC-1065 analogues on cell survival and cell cycle of Chinese hamster ovary cells.
    Adams EG; Badiner GJ; Bhuyan BK
    Cancer Res; 1988 Jan; 48(1):109-16. PubMed ID: 2446739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells.
    Côté S; Momparler RL
    Anticancer Drugs; 1993 Jun; 4(3):327-33. PubMed ID: 7689364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction.
    Lee CS; Pfeifer GP; Gibson NW
    Biochemistry; 1994 May; 33(19):6024-30. PubMed ID: 8180230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction by adozelesin and hydroxyurea of origin recognition complex-dependent DNA damage and DNA replication checkpoints in Saccharomyces cerevisiae.
    Weinberger M; Trabold PA; Lu M; Sharma K; Huberman JA; Burhans WC
    J Biol Chem; 1999 Dec; 274(50):35975-84. PubMed ID: 10585487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of initiation of simian virus 40 DNA replication in infected BSC-1 cells by the DNA alkylating drug adozelesin.
    Cobuzzi RJ; Burhans WC; Beerman TA
    J Biol Chem; 1996 Aug; 271(33):19852-9. PubMed ID: 8702695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay.
    Hidalgo M; Izbicka E; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
    Anticancer Drugs; 1999 Mar; 10(3):295-302. PubMed ID: 10327036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065.
    Li LH; Kelly RC; Warpehoski MA; McGovren JP; Gebhard I; DeKoning TF
    Invest New Drugs; 1991 May; 9(2):137-48. PubMed ID: 1874598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of DNA damage responses by adozelesin is S phase-specific and dependent on active replication forks.
    Liu JS; Kuo SR; Beerman TA; Melendy T
    Mol Cancer Ther; 2003 Jan; 2(1):41-7. PubMed ID: 12533671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation spectra induced by adozelesin in the supF gene of human XP-A fibroblasts.
    Lee SY; Pfeifer GP; Lee CS
    Arch Pharm Res; 2010 Apr; 33(4):633-6. PubMed ID: 20422374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of cell-cycle kinetics of alkylating agent adolezesin in gynecological cancer cell lines: correlation with drug-induced cytotoxicity.
    Nguyen HN; Sevin BU; Averette H; Perras J; Ramos R; Donato D
    J Cancer Res Clin Oncol; 1992; 118(7):515-22. PubMed ID: 1624543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.
    Foster BJ; LoRusso PM; Poplin E; Zalupski M; Valdivieso M; Wozniak A; Flaherty L; Kasunic DA; Earhart RH; Baker LH
    Invest New Drugs; 1996; 13(4):321-6. PubMed ID: 8824350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.